|
2016 Journal Article The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphomaJones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R. and Gandhi, M. K. (2016). The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 183 (2), 206-220. doi: 10.1111/cei.12716 |
|
2016 Conference Publication The IRE1/XBP1) pathway is a critical regulatory hub for human NK-cell mediated lysis and motility that modulates the actin-binding protein XIRP1Gandhi, M. K., Mujaj, S., Vari, F., Cui, Q., Nourse, J. P., Han, E. and Cristino, A. (2016). The IRE1/XBP1) pathway is a critical regulatory hub for human NK-cell mediated lysis and motility that modulates the actin-binding protein XIRP1. International Congress of Immunology (ICI), Melbourne Australia, 21-26 August 2016. Hoboken, NJ United States: Wiley-Blackwell Publishing. |
|
2016 Journal Article Whole blood EBV-DNA: a surrogate for immune dysfunction in aggressive lymphoma?Cui, Qingyan and Gandhi, Maher K. (2016). Whole blood EBV-DNA: a surrogate for immune dysfunction in aggressive lymphoma?. Leukemia and Lymphoma, 57 (3), 507-508. doi: 10.3109/10428194.2015.1087522 |
|
2016 Conference Publication A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell LymphomaGandhi, Maher K., Arpon, David, Keane, Colm, Han, Erica, Tobin, Josh, Bird, Robert, Hertzberg, Mark S., Self, Marlene, Cross, Donna, Hernandez, Annette and Vari, Frank (2016). A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego CA, United States, 3-6 December 2016. Washington, DC United States: American Society of Hematology. |
|
2016 Conference Publication Low-dose doxorubicin reduces an immunosuppressive Ly6C(lo) monocyte population to improve efficacy of anti-41BB monoclonal antibody against B cell lymphomaMckee, S. J., Doff, B. L., Gandhi, M. K. and Mattarollo, S. R. (2016). Low-dose doxorubicin reduces an immunosuppressive Ly6C(lo) monocyte population to improve efficacy of anti-41BB monoclonal antibody against B cell lymphoma. International Congress of Immunology (ICI), Melbourne, Australia, Aug 21-26, 2016. Weinheim, Germany: Wiley - V C H Verlag GmbH & Co. KGaA. doi: 10.1002/eji.201670200 |
|
2015 Journal Article Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patientsTaylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2015). Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Nephrology Dialysis Transplantation, 30 (10), 1774-1779. doi: 10.1093/ndt/gfv260 |
|
2015 Journal Article Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyKeane, Colm, Vari, Frank, Hertzberg, Mark, Le Cao, Kim-Anh, Green, Michael R., Han, Erica, Seymour, John F., Hicks, Rodney J., Gill, Devinder, Crooks, Pauline, Gould, Clare, Jones, Kimberley, Griffiths, Lyn R., Talaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology, 2 (10), e445-e455. doi: 10.1016/S2352-3026(15)00150-7 |
|
2015 Journal Article Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingKurtz, David M., Green, Michael R., Bratman, Scott V., Scherer, Florian, Liu, Chih Long, Kunder, Christian A., Takahashi, Kazuhiro, Glover, Cynthia, Keane, Colm, Kihira, Shingo, Visser, Brendan, Callahan, Jason, Kong, Katherine A., Faham, Malek, Corbelli, Karen S., Miklos, David, Advani, Ranjana H., Levy, Ronald, Hicks, Rodney J., Hertzberg, Mark, Ohgami, Robert S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125 (24), 3679-3687. doi: 10.1182/blood-2015-03-635169 |
|
2015 Journal Article HLA class I associations with EBV+ post-transplant lymphoproliferative disorderJones, Kimberley, Wockner, Leesa, Thornton, Alycia, Gottlieb, David, Ritchie, David S, Seymour, John F, Kumarasinghe, Gayathri and Gandhi, Maher K (2015). HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transplant Immunology, 32 (2), 126-130. doi: 10.1016/j.trim.2015.02.005 |
|
2015 Conference Publication The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)Keane, Colm, Jones, Kimberly, Gould, Clare, Hamm, David, Wood, Peter, Birch, Simone, Crooks, Pauline, Green, Michael R., Taulaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL). 55th Annual Meeting and Exposition of the American-Society-of-Hematology, New Orleans, LA, United States, 7-10 December 2013. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2015 Conference Publication Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology. |
|
2015 Conference Publication Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after FourHertzberg, Mark S., Gandhi, Maher K., Butcher, Belinda, Columbus, Ruth, Taper, John, Trotman, Judith, Gill, Devinder, Ho, Shir-Jing, Fay, Kelth, Cull, Gavin, Grigg, Andrew P., Chong, Geoff, Lewis, Ian D., Milliken, Sam, Renwick, William, Hahn, Uwe, Filshie, Robin, Watson, Anne-Marie, Kannourakis, George, Wolf, Max, Wirth, Andrew, Warburton, Pauline Therese, Larsen, Stephen Robert, Seymour, John F. and Hicks, Rodney (2015). Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four. 57th Annual Meeting of the American Society of Hematology, Orlando, United States, Dec 05-08, 2015. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood.V126.23.815.815 |
|
2015 Journal Article Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapiesScott, Linda M. and Gandhi, Maher K. (2015). Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Reviews, 29 (6), 405-415. doi: 10.1016/j.blre.2015.06.002 |
|
2015 Conference Publication Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratiosLecao K.-A., Keane C., Han E., Talaulikar D. and Gandhi M. (2015). Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios. Scientific Stream at Big Data in Health Analytics 2015, BigData 2015, Sydney; Australia, October 20, 2015-October 21, 2015. Aachen, Germany: Rheinisch-Westfaelische Technische Hochschule Aachen. |
|
2015 Book Chapter Serum CD163 and TARC as circulating biomarkers in Hodgkin LymphomaJones, Kimberley, Seymour, Louise and Gandhi, Maher K. (2015). Serum CD163 and TARC as circulating biomarkers in Hodgkin Lymphoma. Biomarkers in cancer. (pp. 955-978) edited by Victor R. Preedy and Vinood B. Patel. Dordrecht, Netherlands: Springer. doi: 10.1007/978-94-007-7681-4_5 |
|
2014 Journal Article A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumorsFink, S. E. K., Gandhi, M. K., Nourse, J. P., Keane, C., Jones, K., Crooks, P., Johrens, K., Korfel, A., Schmidt, H., Neumann, S., Tiede, A., Jager, U., Duhrsen, U., Neuhaus, R., Dreyling, M., Borchert, K., Sudhoff, T., Riess, H., Anagnostopoulos, I. and Trappe, R. U. (2014). A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. American Journal of Transplantation, 14 (11), 2577-2587. doi: 10.1111/ajt.12858 |
|
2014 Journal Article A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)Tran, Huyen, Brighton, Tim, Grigg, Andrew, McRae, Simon, Dixon, Joanna, Thurley, Daniel, Gandhi, Maher K., Truman, Matt, Marlton, Paula and Catalano, John (2014). A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). British Journal of Haematology, 167 (2), 243-251. doi: 10.1111/bjh.13029 |
|
2014 Journal Article In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin’s lymphoma (NHL)Aya-Bonilla, Carlos, Camilleri, Emily, Haupt, Larisa M., Lea, Rod, Gandhi, Maher K. and Griffiths, Lyn R. (2014). In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin’s lymphoma (NHL). BMC Genomics, 15 (390) 390, 1-12. doi: 10.1186/1471-2164-15-390 |
|
2014 Journal Article The presence of KIR2DS5 confers protection against adult immune thrombocytopeniaSeymour, L. A., Nourse, J. P., Crooks, P., Wockner, L., Bird, R., Tran, H. and Gandhi, M. K. (2014). The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue Antigens, 83 (3), 154-160. doi: 10.1111/tan.12295 |
|
2014 Journal Article FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorderZimmermann, Heiner, Weiland, Theresa, Nourse, Jamie P., Gandhi, Maher K., Reinke, Petra, Neuhaus, Ruth, Karbasiyan, Mohsen, Gärtner, Barbara, Anagnostopoulos, Ioannis, Riess, Hanno, Trappe, Ralf and Oertel, Stephan (2014). FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorder. Journal of Immunology Research, 264723 264723, 1-6. doi: 10.1155/2014/264723 |
